BFM
GNMX

Boothbay Fund Management’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Boothbay Fund Management’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-15,170
Closed -$84K – 1015
2016
Q3 		$84K Buy
+15,170
New +$86.5K 0.02% 653

Other funds holding GNMX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Boothbay Fund Management's GNMX Position: Q4 2016 in Review

Boothbay Fund Management sold out of Aevi Genomic Medicine Inc (GNMX) in Q4 2016, closing a stake of 15,170 shares — an estimated $84K sold.

Boothbay Fund Management first reported a position in GNMX in Q3 2016 and held it in 1 quarter. The position peaked at $84K in Q3 2016. 76 funds tracked by Wall St. Rank hold GNMX as of Q4 2016.

  • Boothbay Fund Management reported no remaining Aevi Genomic Medicine Inc position as of Q4 2016 after selling out during the quarter.
  • Boothbay Fund Management sold 15,170 Aevi Genomic Medicine Inc shares in Q4 2016, an estimated $84K.
  • Boothbay Fund Management first reported a position in Aevi Genomic Medicine Inc in Q3 2016 and held it in 1 quarter.
  • Boothbay Fund Management's Aevi Genomic Medicine Inc position peaked at $84K in Q3 2016.
  • 76 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q4 2016.

Based on Boothbay Fund Management's 13F filing for Q4 2016, filed 15 Feb 2017.